Sugi Predict

Sugi Predict / Targets / S1PR5

S1PR5

Sphingosine 1-phosphate receptor 5 · Q9H228 · S1PR5 on Sugi Atlas →

115,586 patent compounds predicted against S1PR5, 55,622 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL51920 SCHEMBL51920 0.81 13/20
SCHEMBL60775 SCHEMBL60775 0.56 9/20
SCHEMBL79372 SCHEMBL79372 0.53 9/20
SCHEMBL86694 SCHEMBL86694 0.53 9/20
SCHEMBL86989 SCHEMBL86989 0.53 9/20
SCHEMBL81356 SCHEMBL81356 0.56 8/20
SCHEMBL79788 SCHEMBL79788 0.51 8/20
SCHEMBL36037 SCHEMBL36037 0.72 7/20
SCHEMBL82307 SCHEMBL82307 0.46 7/20
SCHEMBL36132 SCHEMBL36132 0.58 6/20
SCHEMBL86782 SCHEMBL86782 0.48 6/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL78732) 0.47 6/20
SCHEMBL80990 SCHEMBL80990 0.46 6/20
SCHEMBL86523 SCHEMBL86523 0.46 6/20
SCHEMBL86710 SCHEMBL86710 0.46 6/20
SCHEMBL82333 SCHEMBL82333 0.46 6/20
SCHEMBL86792 SCHEMBL86792 0.46 6/20
SCHEMBL79188 SCHEMBL79188 0.39 6/20
SCHEMBL86789 SCHEMBL86789 0.38 6/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL81400) 0.37 6/20

Clinical trials — most relevant to S1PR5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis PHASE4WITHDRAWN
Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study PHASE4COMPLETED
Sphingosine-1-phosphate and Pneumonia PHASE2/PHASE3UNKNOWN
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 PHASE3COMPLETED
Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients PHASE2/PHASE3COMPLETED
A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS PHASE3COMPLETED
A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus PHASE3ACTIVE_NOT_RECRUITING
Phase 2 Study of Fingolimod in Lung Cancers PHASE2RECRUITING
Repurposing Siponimod for Alzheimer's Disease PHASE2RECRUITING
Fingolimod in Schizophrenia Patients PHASE2COMPLETED
Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation PHASE2ENROLLING_BY_INVITATION
A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers. PHASE1COMPLETED
Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis PHASE1COMPLETED
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia nanUNKNOWN
Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study nanUNKNOWN
Vulvodynia: Identification of Potential Relevant Biomarkers nanCOMPLETED
Disease Control in RRMS Transferring Treatment From Natalizumab to Fingolimod nanCOMPLETED
Effects of Fingolimod on Heart Rhythm and Heart Rate Variability in Patients With Multiple Sclerosis nanUNKNOWN
Development of Therapeutic Approaches Modulating Molecular Targets Implicated on Cancer Stem Cell-related Aggressiveness nanUNKNOWN
Longitudinal Assessment of Marrow and Blood in Patients With Glioblastoma nanSUSPENDED
Identification of Biomarkers and Molecular Targets Involved on Intervertebral Disc Degeneration and Discogenic Pain nanUNKNOWN
Studying Lipids as Potential Biomarkers in Patients With Fabry Disease nanCOMPLETED
Evaluating the Association Between Sphingolipid Metabolites and Post-hepatectomy Liver Failure nanCOMPLETED
Assessment of Immune Response in Multiple Sclerosis Patients With COVID-19/Vaccination Treated With Ofatumumab and Other Disease Modifying Therapies nanCOMPLETED
Effect of Plasma Ceramides on Peripheral Vascular Function nanCOMPLETED
An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis nanRECRUITING
PRIMUS : Real World Usage for Real World Evidence of CDSS Use in Multiple Sclerosis nanNOT_YET_RECRUITING
The ASTERS Study: Assessing the Role of Sphingolipids in AcuTE Respiratory Distress Syndrome (ARDS) nanCOMPLETED
Plasma Dihydroceramides Are Associated With Hepatic Steatosis in Type 1 and Type 2 Diabetes nanCOMPLETED
Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a S1PR5 binder may also engage these)

ProteinNameSimilarity
Q9JKM5 — 1.000 Q9JKM5 →
Q91X56 — 1.000 Q91X56 →
Q684M3 — 1.000 Q684M3 →
O54897 — 0.978 O54897 →
PTGER1 Prostaglandin E2 receptor EP1 subtype 0.976 landscape →
GPR27 Probable G-protein coupled receptor 27 0.975 landscape →
Q9JJH3 — 0.974 Q9JJH3 →
P35375 — 0.974 P35375 →
S1PR4 Sphingosine 1-phosphate receptor 4 0.972 landscape →
P70597 — 0.972 P70597 →
Q9BGL8 — 0.969 Q9BGL8 →
PTGIR Prostacyclin receptor 0.965 landscape →
AVPR2 Vasopressin V2 receptor 0.963 landscape →
P79393 — 0.961 P79393 →
P32307 — 0.957 P32307 →
Q8HYC3 — 0.957 Q8HYC3 →
O77808 — 0.957 O77808 →
Q00788 — 0.956 Q00788 →
P48044 — 0.955 P48044 →
Q9Z0L1 — 0.955 Q9Z0L1 →
O88721 — 0.954 O88721 →
GALR3 Galanin receptor type 3 0.953 landscape →
MLNR Motilin receptor 0.953 landscape →
UTS2R Urotensin-2 receptor 0.953 landscape →
HTR6 5-hydroxytryptamine receptor 6 0.950 landscape →
P30987 — 0.950 P30987 →
P34978 — 0.949 P34978 →
P43252 — 0.949 P43252 →
Q96N19 — 0.948 Q96N19 →
P43253 — 0.947 P43253 →